Prognosis in systemic lupus erythematosus

T-cell depletion improves outcome after autologous stem cell transplant in patients with systemic lupus erythematosus (SLE)

“…[1][2][3][4] The goal of hematopoietic stem cell transplant (HSCT) in treatment-refractory SLE is to ablate autoreactive immune cells through high-dose immunosuppressive therapy followed by HSCT. Currently, there are insufficient clinical data to compare unmanipulated vs T-cell-depleted grafts.…”

Drug combination therapy of systemic lupus erythematosus

“…During the past few decades, the survival of systemic lupus erythematosus (SLE) patients has steadily improved, so much so that it has become a minor issue with a mortality rate of approximately 1-2% per annum [2,11]. The main problem today for lupus patients concerns their quality of life and the risk of loss of kidney function.…”

“…The main problem today for lupus patients concerns their quality of life and the risk of loss of kidney function. Indeed, too many patients still lose this function (9% after 5 years of disease, 17% after 10 years) [2]. The aim of today's management of SLE is thus centred on allowing patients a good quality of life in both professional and personal terms, including the possibility of having children.…”

Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus

“…[1][2][3][4][5][6][7][8] High-risk patients are at greater risk with a 20% 1-year, 35% 5-year and 45% 10-year mortality (Figure 1). Patients at high risk for lethal complications may be identified by renal disease, hypertension, lung involvement, anemia, thrombocytopenia, and antibodies to phospholipids, or active disease demonstrated by a high disease activity index score despite therapy.…”

“…Patients at high risk for lethal complications may be identified by renal disease, hypertension, lung involvement, anemia, thrombocytopenia, and antibodies to phospholipids, or active disease demonstrated by a high disease activity index score despite therapy. [1][2][3][4][5][6][7][8] For this group of patients who have failed pulse intravenous cyclophosphamide, autologous hematopoietic stem cell transplanation (HSCT) has induced drug-free, clinical and serologic remission for more than 4 years. [9][10][11] Mobilization and conditioning regimen Mobilization of stem cells from the blood with G-CSF alone has been demonstrated to precipitate a flare of some autoimmune diseases.…”